ApoB discordance

1. ApoB discordance is associated with elevated Lp in humans (ApoB-discordant versus concordant-low ACS patients; Lp(a) >50 mg/dL) (94.2% versus 50.8%).

   “Strikingly, Lp(a) >50 mg/dL was present in 94.2% of discordant patients versus 50.8% of concordant-low individuals.”

   HumansApoB-discordant versus concordant-low ACS patients; Lp(a) >50 mg/dL1 month

   LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy

   ESC Congress 2026 abstract·Oct 26, 2026

More on Elevated Lp

1. ApoB discordance is associated with C-reactive protein in humans (ApoB-discordant versus concordant-low ACS patients achieving LDL-C target) (Median hsCRP 0.72 vs 0.48 mg/L).

   “This discordant group exhibited higher triglycerides (149 vs 121 mg/dL), higher remnant cholesterol (21 vs 16 mg/dL), and a higher median hsCRP (0.72 vs 0.48 mg/L) than concordant-low patients.”

   HumansApoB-discordant versus concordant-low ACS patients achieving LDL-C target1 month

   LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy

   ESC Congress 2026 abstract·Oct 26, 2026

More on C-reactive protein

1. ApoB discordance is associated with triglyceride in humans (ApoB-discordant versus concordant-low ACS patients achieving LDL-C target) (Triglycerides 149 vs 121 mg/dL; remnant cholesterol 21 vs 16 mg/dL).

   “This discordant group exhibited higher triglycerides (149 vs 121 mg/dL), higher remnant cholesterol (21 vs 16 mg/dL)”

   HumansApoB-discordant versus concordant-low ACS patients achieving LDL-C target1 month

   LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy

   ESC Congress 2026 abstract·Oct 26, 2026

More on Triglyceride

1. LDL-C target achievement is associated with ApoB discordance in humans (86 patients (23.8%) had ApoB >65 mg/dL despite target LDL-C).

   “However, among LDL achievers, 86 patients (23.8%) demonstrated ApoB >65 mg/dL despite target LDL-C.”

   HumansACS patients achieving corrected LDL-C <55 mg/dL after PCI and triple oral lipid-lowering therapy1 monthn = 350

   LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy

   ESC Congress 2026 abstract·Oct 26, 2026

More on LDL-C target achievement